Inhibitors of cyclo-oxygenase 2: A new class of anticancer agents?

Giampietro Gasparini, Raffaele Longo, Roberta Sarmiento, Alessandro Morabito

Research output: Contribution to journalArticlepeer-review


Experimental studies have shown that cyclooxygenase 2 (COX2) is involved in tumour development and progression. Selective inhibitors of COX2 (coxibs) block tumour growth through many mechanisms, especially by antiangiogenic and proapoptotic effects. In experimental models, coxibs potentiate the activity of cytotoxic agents, hormones, and radiotherapy. Large clinical studies have shown chemopreventive activity of coxibs in colorectal cancer. The findings of preclinical studies coupled with the overexpression of COX2 observed in advanced human tumours are the basis for new therapeutic anticancer strategies based on combinations of coxibs with other anticancer treatment modalities. Early clinical studies have documented the feasibility, good tolerability, and promising activity of coxibs combined with chemotherapy in patients with advanced colorectal and non-small-cell lung cancers. Here, we describe the recent findings on the antitumour effects of coxibs with particular focus on the opportunities that have emerged for treatment of cancer.

Original languageEnglish
Pages (from-to)605-615
Number of pages11
JournalThe Lancet Oncology
Issue number10
Publication statusPublished - Oct 1 2003

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'Inhibitors of cyclo-oxygenase 2: A new class of anticancer agents?'. Together they form a unique fingerprint.

Cite this